Stephen J. Hill - Oct 27, 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Operating Officer
Signature
/s/ Mark Meltz, Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Oct 27, 2025
Transactions value $
$0
Form type
4
Date filed
10/29/2025, 05:42 PM
Previous filing
Aug 22, 2025
Next filing
Nov 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hill Stephen J. Chief Operating Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO /s/ Mark Meltz, Attorney-in-Fact 2025-10-29 0001866154

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LYEL Common Stock 15.8K Oct 27, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +75K $0.00 75K Oct 27, 2025 Common Stock 75K $17.23 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the option shares will vest on April 27, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.